Company intelligence / Profile preview

Clinvue

Melbourne, Victoria, Australia

Ownership: Private
Employees: ~100
Development stage: Other

Overview

SCENESSE® (afamelanotide) is approved and commercialized for EPP in the US and EU, with ongoing expansion, including a Canadian submission. Clinical results show prevention of phototoxicity in EPP; investigational pipeline addresses vitiligo and potentially DNA repair.

Therapeutic areas: DermatologyRare Diseases
Modalities: PeptideSmall molecule
Industry: Biotech

Partnerships

Tareen Dermatology (clinical trials for vitiligo)

Beyond the preview

Go deeper on Clinvue.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Clinvue.

Explore the full profile